News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Madrigal Pharmaceuticals
NEWS
JOBS
IN THE PRESS
NEWS
Deals
3 Small Biotechs Big Drugmakers are Making Googly Eyes At
A look at three small biotechs that big drugmakers are drooling over.
January 29, 2018
·
1 min read
Biotech Bay
8 Possible Biopharma Takeover Targets for 2018
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
December 18, 2017
·
5 min read
·
Mark Terry
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Pharm Country
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
March 18, 2024
·
5 min read
Pharm Country
Madrigal Pharmaceuticals Announces Proposed Public Offering - March 18, 2024
March 18, 2024
·
5 min read
Policy
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
March 14, 2024
·
4 min read
FDA
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
March 14, 2024
·
16 min read
Pharm Country
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 06, 2024
March 6, 2024
·
2 min read
Policy
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
March 5, 2024
·
9 min read
Business
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
·
12 min read
Business
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
February 28, 2024
·
3 min read
Deals
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 21, 2024
February 21, 2024
·
1 min read
Drug Development
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
February 8, 2024
·
12 min read
